Kyverna Therapeutics signs licence deal with Oxford Biomedica for LentiVector platform
Kyverna Therapeutics, a clinical-stage cell therapy company, has entered into a non-exclusive, multi-year licence and supply agreement with Oxford Biomedica, a viral vector contract and development manufacturing organisation